Protalix Biotherapeutics Stock Price History
| PLX Stock | USD 1.69 0.01 0.60% |
Below is the normalized historical share price chart for Protalix Biotherapeutics extending back to April 09, 1996. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Protalix Biotherapeutics stands at 1.69, as last reported on the 28th of November, with the highest price reaching 1.73 and the lowest price hitting 1.68 during the day.
If you're considering investing in Protalix Stock, it is important to understand the factors that can impact its price. Protalix Biotherapeutics is relatively risky given 3 months investment horizon. Protalix Biotherapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.22, which implies the firm had a 0.22% return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.02% are justified by taking the suggested risk. Use Protalix Biotherapeutics Risk Adjusted Performance of 0.1829, coefficient of variation of 439.0, and Semi Deviation of 2.37 to evaluate company specific risk that cannot be diversified away.
At this time, Protalix Biotherapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year. Total Stockholder Equity is likely to rise to about 35.2 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 51 M in 2024. . Price Earnings Ratio is likely to rise to 15.18 in 2024, whereas Price To Sales Ratio is likely to drop 1.74 in 2024. Protalix Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 15th of May 1998 | 200 Day MA 1.1875 | 50 Day MA 1.2004 | Beta 0.672 |
Protalix |
Sharpe Ratio = 0.2208
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PLX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.62 actual daily | 41 59% of assets are more volatile |
Expected Return
| 1.02 actual daily | 20 80% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Protalix Biotherapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protalix Biotherapeutics by adding it to a well-diversified portfolio.
Price Book 3.8137 | Enterprise Value Ebitda 5.6271 | Price Sales 3.2702 | Shares Float 54.7 M | Wall Street Target Price 14 |
Protalix Biotherapeutics Stock Price History Chart
There are several ways to analyze Protalix Stock price data. The simplest method is using a basic Protalix candlestick price chart, which shows Protalix Biotherapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | November 25, 2024 | 1.71 |
| Lowest Price | September 6, 2024 | 1.0 |
Protalix Biotherapeutics November 28, 2024 Stock Price Synopsis
Various analyses of Protalix Biotherapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Protalix Stock. It can be used to describe the percentage change in the price of Protalix Biotherapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Protalix Stock.| Protalix Biotherapeutics Price Action Indicator | (0.01) | |
| Protalix Biotherapeutics Price Rate Of Daily Change | 1.01 | |
| Protalix Biotherapeutics Price Daily Balance Of Power | 0.20 |
Protalix Biotherapeutics November 28, 2024 Stock Price Analysis
Protalix Stock Price History Data
The price series of Protalix Biotherapeutics for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 has a statistical range of 0.81 with a coefficient of variation of 18.6. The price distribution for the period has arithmetic mean of 1.16. The median price for the last 90 days is 1.09. The company completed stock split (1:10) on 20th of December 2019. Protalix Biotherapeutics had dividends distributed to its stock-holders on 2019-12-20.| Open | High | Low | Close | Volume | ||
11/28/2024 | 1.70 | 1.73 | 1.68 | 1.69 | ||
| 11/27/2024 | 1.70 | 1.73 | 1.68 | 1.69 | 173,373 | |
| 11/26/2024 | 1.69 | 1.73 | 1.65 | 1.68 | 402,345 | |
| 11/25/2024 | 1.73 | 1.73 | 1.68 | 1.71 | 327,956 | |
| 11/22/2024 | 1.68 | 1.78 | 1.66 | 1.69 | 545,617 | |
| 11/21/2024 | 1.70 | 1.71 | 1.60 | 1.66 | 530,385 | |
| 11/20/2024 | 1.65 | 1.74 | 1.61 | 1.69 | 817,971 | |
| 11/19/2024 | 1.66 | 1.75 | 1.58 | 1.63 | 533,660 | |
| 11/18/2024 | 1.42 | 1.72 | 1.40 | 1.66 | 1,786,170 | |
| 11/15/2024 | 1.38 | 1.41 | 1.33 | 1.40 | 328,811 | |
| 11/14/2024 | 1.26 | 1.41 | 1.26 | 1.41 | 1,459,725 | |
| 11/13/2024 | 1.28 | 1.31 | 1.23 | 1.24 | 305,066 | |
| 11/12/2024 | 1.22 | 1.34 | 1.20 | 1.32 | 471,640 | |
| 11/11/2024 | 1.18 | 1.21 | 1.18 | 1.20 | 215,084 | |
| 11/08/2024 | 1.17 | 1.22 | 1.16 | 1.16 | 161,786 | |
| 11/07/2024 | 1.19 | 1.24 | 1.16 | 1.16 | 331,871 | |
| 11/06/2024 | 1.33 | 1.33 | 1.22 | 1.22 | 139,513 | |
| 11/05/2024 | 1.30 | 1.32 | 1.27 | 1.30 | 159,034 | |
| 11/04/2024 | 1.26 | 1.36 | 1.26 | 1.28 | 969,260 | |
| 11/01/2024 | 1.19 | 1.26 | 1.18 | 1.25 | 294,746 | |
| 10/31/2024 | 1.18 | 1.18 | 1.14 | 1.17 | 113,348 | |
| 10/30/2024 | 1.18 | 1.18 | 1.17 | 1.17 | 138,011 | |
| 10/29/2024 | 1.17 | 1.18 | 1.17 | 1.17 | 127,863 | |
| 10/28/2024 | 1.10 | 1.14 | 1.07 | 1.13 | 236,046 | |
| 10/25/2024 | 1.03 | 1.09 | 1.03 | 1.08 | 129,033 | |
| 10/24/2024 | 1.04 | 1.04 | 1.02 | 1.03 | 48,006 | |
| 10/23/2024 | 1.04 | 1.05 | 1.02 | 1.02 | 87,294 | |
| 10/22/2024 | 1.06 | 1.09 | 1.01 | 1.06 | 297,398 | |
| 10/21/2024 | 1.08 | 1.09 | 1.05 | 1.06 | 187,585 | |
| 10/18/2024 | 1.08 | 1.10 | 1.08 | 1.09 | 74,056 | |
| 10/17/2024 | 1.10 | 1.11 | 1.08 | 1.09 | 146,423 | |
| 10/16/2024 | 1.10 | 1.11 | 1.07 | 1.09 | 125,266 | |
| 10/15/2024 | 1.06 | 1.09 | 1.04 | 1.08 | 111,018 | |
| 10/14/2024 | 1.08 | 1.08 | 1.04 | 1.06 | 127,404 | |
| 10/11/2024 | 1.02 | 1.08 | 1.01 | 1.08 | 288,776 | |
| 10/10/2024 | 1.02 | 1.02 | 0.99 | 1.00 | 129,217 | |
| 10/09/2024 | 1.02 | 1.02 | 1.01 | 1.01 | 100,049 | |
| 10/08/2024 | 1.04 | 1.04 | 0.99 | 1.02 | 102,257 | |
| 10/07/2024 | 1.05 | 1.07 | 1.01 | 1.02 | 170,394 | |
| 10/04/2024 | 1.07 | 1.08 | 1.02 | 1.08 | 116,384 | |
| 10/03/2024 | 1.02 | 1.03 | 1.01 | 1.01 | 55,251 | |
| 10/02/2024 | 1.02 | 1.05 | 1.02 | 1.02 | 46,476 | |
| 10/01/2024 | 1.02 | 1.05 | 1.01 | 1.05 | 62,983 | |
| 09/30/2024 | 1.05 | 1.08 | 1.00 | 1.02 | 247,879 | |
| 09/27/2024 | 1.06 | 1.11 | 1.05 | 1.05 | 239,068 | |
| 09/26/2024 | 1.09 | 1.11 | 1.06 | 1.07 | 86,392 | |
| 09/25/2024 | 1.08 | 1.10 | 1.07 | 1.09 | 74,331 | |
| 09/24/2024 | 1.11 | 1.13 | 1.08 | 1.08 | 132,956 | |
| 09/23/2024 | 1.12 | 1.14 | 1.09 | 1.12 | 88,489 | |
| 09/20/2024 | 1.15 | 1.17 | 1.10 | 1.10 | 124,337 | |
| 09/19/2024 | 1.15 | 1.16 | 1.12 | 1.15 | 110,429 | |
| 09/18/2024 | 1.10 | 1.15 | 1.09 | 1.09 | 172,648 | |
| 09/17/2024 | 1.09 | 1.12 | 1.07 | 1.10 | 150,218 | |
| 09/16/2024 | 1.07 | 1.09 | 1.06 | 1.09 | 82,746 | |
| 09/13/2024 | 1.04 | 1.09 | 1.04 | 1.05 | 89,589 | |
| 09/12/2024 | 1.06 | 1.10 | 1.01 | 1.06 | 152,008 | |
| 09/11/2024 | 1.04 | 1.05 | 1.00 | 1.04 | 119,203 | |
| 09/10/2024 | 1.01 | 1.03 | 0.99 | 1.02 | 116,259 | |
| 09/09/2024 | 0.98 | 1.04 | 0.98 | 1.01 | 140,594 | |
| 09/06/2024 | 1.02 | 1.03 | 0.99 | 1.00 | 68,828 | |
| 09/05/2024 | 1.02 | 1.05 | 1.01 | 1.02 | 74,062 |
About Protalix Biotherapeutics Stock history
Protalix Biotherapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Protalix is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Protalix Biotherapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Protalix Biotherapeutics stock prices may prove useful in developing a viable investing in Protalix Biotherapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 82.4 M | 86.5 M | |
| Net Loss | -13.4 M | -14.1 M |
Protalix Biotherapeutics Stock Technical Analysis
Protalix Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Protalix Biotherapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Protalix Biotherapeutics' price direction in advance. Along with the technical and fundamental analysis of Protalix Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Protalix to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1829 | |||
| Jensen Alpha | 1.12 | |||
| Total Risk Alpha | 0.3426 | |||
| Sortino Ratio | 0.2774 | |||
| Treynor Ratio | (1.37) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.